Can a smart drug outperform chemotherapy for a common breast cancer subtype?
NCT ID NCT05814354
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental drug called SHR-A1811 can slow the growth of HER2-low breast cancer that has returned or spread, compared to standard chemotherapy chosen by the doctor. The study enrolls about 551 adults whose tumors have low levels of HER2, a protein targeted by the drug. Participants are randomly assigned to receive either SHR-A1811 or one of several chemotherapy drugs. The main goal is to see if SHR-A1811 extends the time without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811, an experimental antibody-drug conjugate, compared with standard chemotherapy options (capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel).
- What this could lead to
- If successful, SHR-A1811 could offer a new, more effective treatment option for people with HER2-low metastatic breast cancer, potentially extending the time before the disease progresses.
- What could go wrong
- This is a phase III trial, but results are not yet known. The drug may not prove superior to chemotherapy, and antibody-drug conjugates can have side effects like fatigue, nausea, or blood-related issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?